Genomma Lab Internacional Announces Results for the Second Quarter 2025

MEXICO CITY, July 23, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB) ("Genomma" or "the Company"), today announced its results for the second quarter of 2025. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise noted.

Comments from Genomma's CEO, Marco Sparvieri

"Genomma's second quarter sales grew +0.5%, or +5.5% excluding Argentina, reflecting a significant Argentine peso depreciation and a weak beverage season in Mexico. Importantly, the company's profitability remained solid, with +4.4% EBITDA growth, margin expanding +89 bps to 23.8%, and a proforma net income increase of +16.6% (excluding non-cash FX related effects). These profitability levels and a 7-day improvement in cash conversion cycle drove a +64.6% free-cash-flow increase for the trailing twelve months. As the company navigates macroeconomic headwinds in 2025, we remain intently focused on executing our growth projects while maintaining an average EBITDA margin of 24% through our ongoing productivity program."

Q2 2025 Financial Summary

The following table provides a summary of the Company's Income Statement, in millions of Mexican pesos.

Q2 2025

% sales

Q2 2024

% sales

% var

Net Sales

4,676.4

100.0 %

4,651.5

100.0 %

+0.5 %

Like-for-like Sales(1)

+0.3 %

Gross Profit

2,969.4

63.5 %

2,977.7